Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Japanese shares fall on profit-taking, pandemic worries

05/26/2021 | 10:51pm EDT

TOKYO, May 27 (Reuters) - Japanese shares retreated on Thursday as investors trimmed their positions after a recent rally, while uncertainties about domestic economic growth due to a possible extension of COVID-19 emergency measures weighed on sentiment.

The Nikkei share average fell 0.69% to 28,445.25 by 0157 GMT, after a gain of 2.1% in five straight sessions. The broader Topix fell 0.39% to 1,913.32.

"We can say the market is down due to profit-taking, but there are also uncertainties ahead of us that are making investors cautions," said Takatoshi Itoshima, strategist at Pictet Asset Management.

"Overseas investors particularly are sceptical about the pace of Japan's COVID-19 vaccine rollouts, while economic outlook remains unclear as Japan is leaning toward extending the state of emergency."

Japan, which is slated to host the Tokyo 2020 Olympics in July, is struggling to contain a fourth wave of infections even as biggest cities are covered under emergency measures.

Tokyo governor Yuriko Koike on Wednesday sought the current state of emergency, originally set to be lifted at the end of May, to be extended for "about another month," while Osaka in the western region has made a similar request.

Investors want to see the impact of the MSCI's regular rebalancing, which will complete by the end of the session, as 29 Japanese shares will be excluded from its main index, Itoshima added.

Shippers and steel makers led the declines, falling 2.05% and 1.46%, respectively, while airliners , up 2.51%, gained the most among the 33 Tokyo Exchanges subindexes.

Astellas Pharma, up 3.26%, was the biggest percentage gainer among the top 30 core Topix names, followed by Keyence.

The underperformers among the Topix 30 were Recruit Holdings Co, down 2.83%, followed by Seven & i Holdings losing 2.48%. (Reporting by Junko Fujita and Kevin Buckland; editing by Uttaresh.V)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. -0.37% 1905 End-of-day quote.19.51%
KEYENCE CORPORATION -1.76% 57000 End-of-day quote.-1.72%
NIKKEI 225 0.73% 27782.42 Real-time Quote.0.50%
RECRUIT HOLDINGS CO., LTD. -3.00% 5635 End-of-day quote.30.41%
SEVEN & I HOLDINGS CO., LTD. 0.34% 5017 End-of-day quote.37.11%
All news about ASTELLAS PHARMA INC.
07/20The U.S. Food and Drug Administration Approves Astellas Pharma Inc.'s Supplem..
CI
07/15Piers Morgan Joins Pharnext's Board of Directors
DJ
07/15Piers Morgan rejoint le Conseil d'Administration de Pharnext
DJ
07/13ExCellThera and Astellas Enters into a License for the Use of Molecule UM171 ..
CI
07/12Affinivax and Astellas Presents Safety and Immunogenicity Data from Phase 2 S..
CI
07/12ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
AQ
07/11ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
PU
07/09ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
BU
06/29ASTELLAS PHARMA : Corporate Governance Report
PU
06/28ASTELLAS PHARMA : Receives Positive CHMP Opinion for EVRENZO (roxadustat) for Ad..
PU
More news
Financials
Sales 2022 1 320 B 12 014 M 12 014 M
Net income 2022 203 B 1 844 M 1 844 M
Net cash 2022 523 B 4 756 M 4 756 M
P/E ratio 2022 17,3x
Yield 2022 2,58%
Capitalization 3 530 B 32 066 M 32 127 M
EV / Sales 2022 2,28x
EV / Sales 2023 2,04x
Nbr of Employees 15 455
Free-Float 99,0%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 1 905,00 JPY
Average target price 2 482,31 JPY
Spread / Average Target 30,3%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.19.51%32 066
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750